School of Medicine, University of Limerick, Limerick, Ireland.
Health Research Institute (HRI), University of Limerick, Limerick, Ireland.
BMC Nephrol. 2023 Jul 6;24(1):203. doi: 10.1186/s12882-023-03251-w.
Abnormalities of serum sodium are associated with increased mortality risk in hospitalised patients, but it is unclear whether, and to what extent other factors influence this relationship. We investigated the impact of dysnatraemia on total and cause-specific mortality in the Irish health system while exploring the concurrent impact of age, kidney function and designated clinical work-based settings.
A retrospective cohort study of 32,666 participants was conducted using data from the National Kidney Disease Surveillance System. Hyponatraemia was defined as < 135 mmol/L and hypernatraemia as > 145 mmol/L with normal range 135-145 mmol/L. Multivariable Cox proportional hazards regression was used to estimate hazard ratios (HR's) and 95% Confidence Intervals (CIs) while penalised spline models further examined patterns of risk.
There were 5,114 deaths (15.7%) over a median follow up of 5.5 years. Dysnatraemia was present in 8.5% of patients overall. In multivariable analysis, both baseline and time-dependent serum sodium concentrations exhibited a U-shaped association with mortality. Hyponatremia was significantly associated with increased risk for cardiovascular [HR 1.38 (1.18-1.61)], malignant [HR: 2.49 (2.23-2.78)] and non-cardiovascular/non-malignant causes of death [1.36 (1.17-1.58)], while hypernatremia was significantly associated with cardiovascular [HR: 2.16 (1.58-2.96)] and non-cardiovascular/ non-malignant deaths respectively [HR: 3.60 (2.87-4.52)]. The sodium-mortality relationship was significantly influenced by age, level of kidney function and the clinical setting at baseline (P < 0.001). For hyponatraemia, relative mortality risks were significantly higher for younger patients (interaction term P < 0.001), for patients with better kidney function, and for patients attending general practice [HR 2.70 (2.15-3.36)] than other clinical settings. For hypernatraemia, age and kidney function remained significant effect modifiers, with patients attending outpatient departments experiencing the greatest risk [HR 9.84 (4.88-18.62)] than patients who attended other clinical locations. Optimal serum sodium thresholds for mortality varied by level of kidney function with a flattening of mortality curve observed for patients with poorer kidney function.
Serum sodium concentrations outside the standard normal range adversly impact mortality and are associated with specific causes of death. The thresholds at which these risks appear to vary by age, level of kidney function, and are modified in specific clinical settings within the health system.
血清钠异常与住院患者的死亡风险增加有关,但目前尚不清楚其他因素是否以及在何种程度上影响这种关系。我们研究了在爱尔兰卫生系统中,低钠血症和高钠血症对总死亡率和特定病因死亡率的影响,同时探讨了年龄、肾功能和指定临床工作场所的并发影响。
利用国家肾脏疾病监测系统的数据,对 32666 名参与者进行了回顾性队列研究。低钠血症定义为<135mmol/L,高钠血症定义为>145mmol/L,正常范围为 135-145mmol/L。多变量 Cox 比例风险回归用于估计危险比(HR)和 95%置信区间(CI),而惩罚样条模型进一步研究了风险模式。
中位随访 5.5 年后,共有 5114 例死亡(15.7%)。总体上,8.5%的患者存在钠异常。在多变量分析中,基线和时间依赖性血清钠浓度均与死亡率呈 U 形关联。低钠血症与心血管[HR 1.38(1.18-1.61)]、恶性[HR:2.49(2.23-2.78)]和非心血管/非恶性死亡原因的风险显著增加相关,而高钠血症与心血管[HR:2.16(1.58-2.96)]和非心血管/非恶性死亡原因的风险显著增加相关[HR:3.60(2.87-4.52)]。钠-死亡率关系受年龄、肾功能水平和基线时的临床环境显著影响(P<0.001)。对于低钠血症,相对死亡率风险在年龄较小的患者中(交互项 P<0.001)、肾功能较好的患者中和在普通科就诊的患者中(HR 2.70(2.15-3.36))显著较高,而在其他临床环境中则较低。对于高钠血症,年龄和肾功能仍然是显著的效应修饰因素,在门诊就诊的患者中风险最高(HR 9.84(4.88-18.62)),而在其他临床地点就诊的患者风险较低。死亡率的最佳血清钠阈值因肾功能水平而异,肾功能较差的患者死亡率曲线趋于平坦。
血清钠浓度超出标准正常范围会对死亡率产生不利影响,并与特定的死亡原因相关。这些风险似乎因年龄、肾功能水平以及健康系统内特定临床环境的影响而变化的阈值。